Heidelberg Pharma (HPHA) Stock Overview
A biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
HPHA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Heidelberg Pharma AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.00 |
| 52 Week High | €5.36 |
| 52 Week Low | €2.11 |
| Beta | 1.65 |
| 1 Month Change | -3.23% |
| 3 Month Change | -28.40% |
| 1 Year Change | 20.00% |
| 3 Year Change | -43.18% |
| 5 Year Change | -23.47% |
| Change since IPO | -94.33% |
Recent News & Updates
Recent updates
ATAC Platform And HDP-101 Trials Will Advance Clinical Frontiers
Heidelberg Pharma's ATAC technology and multiple pipeline candidates offer potential for new revenue streams and long-term growth in earnings.Is Heidelberg Pharma (ETR:HPHA) A Risky Investment?
Feb 16
Heidelberg Pharma AG's (ETR:HPHA) Price In Tune With Revenues
Dec 05Industry Analysts Just Upgraded Their Heidelberg Pharma AG (ETR:HPHA) Revenue Forecasts By 21%
Jul 21Analyst Forecasts For Heidelberg Pharma AG (ETR:HPHA) Are Surging Higher
Oct 16Heidelberg Pharma (ETR:HPHA) Will Have To Spend Its Cash Wisely
Nov 28Heidelberg Pharma AG (ETR:HPHA) Analysts Are More Bearish Than They Used To Be
Mar 27We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully
Mar 15Investors Who Bought Heidelberg Pharma (ETR:HPHA) Shares Five Years Ago Are Now Up 245%
Jan 17
We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully
Dec 14Shareholder Returns
| HPHA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.0% | -0.05% | 0.07% |
| 1Y | 20.0% | -34.3% | 13.5% |
Return vs Industry: HPHA exceeded the German Biotechs industry which returned -34.3% over the past year.
Return vs Market: HPHA exceeded the German Market which returned 13.5% over the past year.
Price Volatility
| HPHA volatility | |
|---|---|
| HPHA Average Weekly Movement | 8.3% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 12.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: HPHA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: HPHA's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 114 | Andreas Pahl | heidelberg-pharma.com |
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, the United States, and internationally. Its lead product candidates include HDP-101, an anti-BCMA antibody, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. The company develops HDP-102, an antibody and the compound Amanitin, which has completed preclinical development for the treatment of non-Hodgkin lymphoma; HDP-103, a proprietary ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for the treatment of gastrointestinal tumors; HDP-201 for the treatment of colorectal cancer; and TAK-ATAC for the treatment of oncology.
Heidelberg Pharma AG Fundamentals Summary
| HPHA fundamental statistics | |
|---|---|
| Market cap | €140.34m |
| Earnings (TTM) | -€26.18m |
| Revenue (TTM) | €3.04m |
Is HPHA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HPHA income statement (TTM) | |
|---|---|
| Revenue | €3.04m |
| Cost of Revenue | €466.00k |
| Gross Profit | €2.57m |
| Other Expenses | €28.75m |
| Earnings | -€26.18m |
Last Reported Earnings
Aug 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.56 |
| Gross Margin | 84.66% |
| Net Profit Margin | -861.83% |
| Debt/Equity Ratio | 0% |
How did HPHA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/30 01:51 |
| End of Day Share Price | 2025/10/30 00:00 |
| Earnings | 2025/08/31 |
| Annual Earnings | 2024/11/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Heidelberg Pharma AG is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bruno Bulic | Baader Helvea Equity Research |
| Christian Weiz | Baader Helvea Equity Research |
| Robin Davison | Edison Investment Research |